TORONTO, Sept. 3, 2024 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) announced today that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for Omvoh® (mirikizumab) for ulcerative colitis (UC) on August 29, 2024, with a letter of intent (LOI). Omvoh is the first and only interleukin-23p19 (IL-23p19) antagonist approved in Canada for the treatment of moderately to severely active UC and is indicated for adult UC patients who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.
Read more at newswire.caLilly Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for OMVOH® (mirikizumab) for adults with moderately to severely active ulcerative colitis (UC)
Newswire.ca - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/Alphabet%20Inc_%20and%20Google%20logos%20seen%20displayed%20on%20a%20smartphone%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
/Phone%20and%20computer%20internet%20network%20by%20Pinkypills%20via%20iStock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)